The Pharmaceutical Journal
Vol 271 No 7273 p607
1 November 2003

This article
Reprint
Photocopy

News summary

Related websites
New England Journal of Medicine abstract (more)

Renal failure with zoledronic acid

Researchers from the Food and Drug Administration in the United States report 72 cases of renal failure associated with use of zoledronic acid (Zometa) in last week's New England Journal of Medicine. They suggest health professionals should monitor renal function, provide adequate hydration and discontinue treatment if renal function deteriorates (2003;349:1676).